Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Rickmer Braren

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-6039-6957; OpenAlex author ID A5007748020, A5124204057. Sources: OpenAlex.

Their work

Papers
41 (first author 2, last author 14)
Trials
0
Grants
0
Labs led
1
Collaborators
128
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 3 papers · 2016: 3 papers · 2017: 3 papers · 2018: none · 2019: 4 papers · 2020: 4 papers · 2021: 5 papers · 2022: 4 papers · 2023: 1 paper · 2024: 3 papers · 2025: 4 papers · 2026: 5 papers

Papers 41

  1. Contrastive virtual staining enhances deep learning-based PDAC subtyping from H&E-stained tissue cores. Co-author DOI 10.1002/path.6491↗
  2. Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-026-69013-y↗
  3. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Co-author DOI 10.1038/s41591-026-04234-8↗
  4. Contrast enhanced CT and MRI interchangeably reflect tumor characteristics in murine pancreatic cancer. Co-author DOI 10.1038/s41598-026-56008-4↗
  5. Hemorrhage-Induced Bias of [18F]FDG PET Signal Interpretation in Pancreatic Ductal Adenocarcinoma Last author DOI 10.21203/rs.3.rs-10932499/v1↗
  6. Correction to: Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine‑induce… Last author DOI 10.1007/s00259-025-07195-1↗
  7. Neural invasion severity is a strong predictor of local recurrence in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2024.109018↗
  8. Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41551-024-01273-9↗
  9. Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatm… Co-author DOI 10.1186/s12885-025-13573-7↗
  10. Prognostic value of deep learning-derived body composition in advanced pancreatic cancer-a retrospective multicenter study. Last author DOI 10.1016/j.esmoop.2023.102219↗
  11. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Co-author DOI 10.1038/s41591-024-03054-y↗
  12. Histology-Based Radiomics for [18F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer. Co-author DOI 10.2967/jnumed.123.266262↗
  13. CT Attenuation of Hepatic Pancreatic Cancer Metastases Correlates with Prognostically Detrimental Metastatic Necrosis. Last author DOI 10.3390/jcm12237319↗
  14. Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascular… Last author DOI 10.1007/s00259-022-05930-6↗
  15. Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s40170-022-00298-5↗
  16. Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. Co-author DOI 10.15252/emmm.202114876↗
  17. High-Resolution, High b-Value Computed Diffusion-Weighted Imaging Improves Detection of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers14030470↗
  18. Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes. Co-author DOI 10.1053/j.gastro.2021.03.051↗
  19. Functional metabolic phenotyping of human pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2021.07.23.452145↗
  20. PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer. Co-author DOI 10.1172/jci.insight.141532↗
  21. [18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s13550-021-00808-4↗
  22. Prediction of Tumor Cellularity in Resectable PDAC from Preoperative Computed Tomography Imaging. Co-author DOI 10.3390/cancers13092069↗
  23. Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. Co-author DOI 10.1172/jci.insight.137809↗
  24. Image-Based Molecular Phenotyping of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/jcm9030724↗
  25. Multiparametric Modelling of Survival in Pancreatic Ductal Adenocarcinoma Using Clinical, Histomorphological, Genetic and Image-Derived Parameters. Last author DOI 10.3390/jcm9051250↗
  26. Deep Convolutional Neural Network-Assisted Feature Extraction for Diagnostic Discrimination and Feature Visualization in Pancreatic Ductal Adenocarcinoma (PDAC… Last author DOI 10.3390/jcm9124013↗
  27. A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imaging. Last author DOI 10.1186/s41747-019-0119-0↗
  28. Borderline-resectable pancreatic adenocarcinoma: Contour irregularity of the venous confluence in pre-operative computed tomography predicts histopathological … Last author DOI 10.1371/journal.pone.0208717↗
  29. A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX … Last author DOI 10.1371/journal.pone.0218642↗
  30. Pancreatic cancer detection and characterization-state of the art cross-sectional imaging and imaging data analysis. First author DOI 10.21037/tgh.2019.05.04↗
  31. Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-017-16826-z↗
  32. Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-15-2432↗
  33. Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene. Co-author DOI 10.18632/oncotarget.16499↗
  34. Next-generation metabolic imaging in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2015-310518↗
  35. Modeling Therapy Response and Spatial Tissue Distribution of Erlotinib in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-15-0165↗
  36. Membranous CD24 drives the epithelial phenotype of pancreatic cancer. Co-author DOI 10.18632/oncotarget.9402↗
  37. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/nm.3952↗
  38. Outcomes of resections for pancreatic adenocarcinoma with suspected venous involvement: a single center experience. Co-author DOI 10.1186/s12893-015-0086-1↗
  39. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience. Co-author DOI 10.1245/s10434-015-4851-2↗
  40. Multimodal molecular imaging of integrin αvβ3 for in vivo detection of pancreatic cancer. Co-author DOI 10.2967/jnumed.113.129619↗
  41. X-ray phase-contrast CT of a pancreatic ductal adenocarcinoma mouse model. First author DOI 10.1371/journal.pone.0058439↗

Closest collaborators

The 25 strongest of 128 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jens Thomas Siveke · 26 shared papers, 2013–2026 · strength 2.80
  2. Irina Heid · 15 shared papers, 2015–2026 · strength 1.94
  3. Georgios A. Kaissis · 15 shared papers, 2019–2025 · strength 1.92
  4. Fabian Karl Lohöfer · 12 shared papers, 2019–2026 · strength 1.55
  5. Roland Michael Schmid · 17 shared papers, 2014–2026 · strength 1.55
  6. Marija Trajkovic‐Arsic · 14 shared papers, 2013–2026 · strength 1.53
  7. Wilko Weichert · 13 shared papers, 2019–2025 · strength 1.37
  8. Felix N. Harder · 9 shared papers, 2020–2025 · strength 1.10
  9. Sebastian Ziegelmayer · 10 shared papers, 2019–2023 · strength 1.09
  10. Helmut Friess · 8 shared papers, 2017–2025 · strength 0.89
  11. Alexander Muckenhuber · 8 shared papers, 2019–2026 · strength 0.86
  12. Hana Algül · 7 shared papers, 2019–2025 · strength 0.74
  13. Friederike Jungmann · 6 shared papers, 2020–2024 · strength 0.68
  14. Iréne Esposito · 9 shared papers, 2014–2026 · strength 0.67
  15. Maximilian Reichert · 6 shared papers, 2016–2025 · strength 0.59
  16. Anna Melissa Schlitter · 5 shared papers, 2015–2025 · strength 0.58
  17. Stephan A. Hahn · 5 shared papers, 2015–2026 · strength 0.57
  18. Jorg H. Kleeff · 7 shared papers, 2014–2026 · strength 0.56
  19. İhsan Ekin Demir · 4 shared papers, 2021–2025 · strength 0.54
  20. Mert Erkan · 6 shared papers, 2015–2026 · strength 0.52
  21. Matthias Wirth · 5 shared papers, 2015–2026 · strength 0.49
  22. Alexander Herner · 5 shared papers, 2015–2026 · strength 0.49
  23. Lucia Liotta · 4 shared papers, 2020–2025 · strength 0.49
  24. Guralp Onur Ceyhan · 4 shared papers, 2019–2025 · strength 0.48
  25. Helmut Frieß · 6 shared papers, 2015–2021 · strength 0.44

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.